|

Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.

RECRUITINGSponsored by Samsung Medical Center
Actively Recruiting
SponsorSamsung Medical Center
Started2024-10-22
Est. completion2025-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07068490

Summary

Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients who underwent PCI
* Use of either clopidogrel, prasugrel, or ticagrelor in combination with aspirin
* No use of PCAB, PPI, or an H2-receptor within the past month

Exclusion Criteria:

* Patients with low GI bleeding risk are taken on PPI
* Patients with high GI bleeding risk do not take PPI

Conditions2

Coronary Artery DiseaseHeart Disease

Interventions2

Guideline-Directed Medical TherapyRoutine use of P-CAB on DAPT

Related trials

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.